Medicus Pharma COO acquires 735K shares, 125K options

Medicus Pharma’s COO received new stock options and common shares as equity compensation, increasing his direct ownership.

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) reported that Chief Operating Officer Smith Andrew Alasdair received equity awards on September 4, 2026. He was granted stock options for 125,000 common shares at an exercise price of $0.1705 per share, scheduled to vest quarterly in four equal installments over one year and expiring on September 4, 2031. He also acquired 735,294 common shares at $0.1705 per share, bringing his direct common share holdings to 735,458 shares and his option holdings to 125,000 shares; no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 860,294 shares

Grant/Award 2 txns

Insider Smith Andrew Alasdair

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	125,000	$0.00	$0.00
Grant/Award	Common Shares, no par value	735,294	$0.1705	$125K

Holdings After Transaction: Stock Option (right to buy) — 125,000 contracts (Direct); Common Shares, no par value — 735,458 shares (Direct)

Footnotes (1)

1. F1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Stock options granted: 125,000 options Option exercise price: $0.1705 per share Option expiration date: September 4, 2031 +3 more

6 metrics

Stock options granted 125,000 options Grant to COO on September 4, 2026

Option exercise price $0.1705 per share Exercise price of options granted September 4, 2026

Option expiration date September 4, 2031 Expiry of options granted to COO

Common shares acquired 735,294 shares Common shares awarded to COO on September 4, 2026 at $0.1705 per share

COO common share holdings after award 735,458 shares Direct common shares held following September 4, 2026 transactions

COO option holdings after award 125,000 options Direct stock options held following September 4, 2026 grant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did MDCX grant to its COO on September 4, 2026?

Medicus Pharma’s COO Smith Andrew Alasdair was granted 125,000 stock options with an exercise price of $0.1705 per share, plus 735,294 common shares at $0.1705 per share as equity compensation.

How many MDCX common shares does the COO hold after this Form 4?

After the reported awards, the COO directly holds 735,458 common shares of Medicus Pharma Ltd., along with 125,000 stock options for additional common shares.

What are the vesting terms of the MDCX stock options granted to the COO?

The option granted on September 4, 2026 is scheduled to vest quarterly in four equal installments over one year, according to the footnote disclosure.

What is the exercise price and expiration date of the COO’s MDCX stock options?

The COO’s stock options have an exercise price of $0.1705 per common share and an expiration date of September 4, 2031.

Was a Rule 10b5-1 trading plan involved in these MDCX transactions?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these equity award transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:02 PM Accepted by SEC EDGAR 09/08/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Andrew Alasdair

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, no par value	09/04/2026		A		735,294	A	$0.1705	735,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.1705	09/04/2026		A		125,000		(1)	09/04/2031	Common Shares	125,000	$0	125,000	D

Explanation of Responses:

1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Andrew A. Smith	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)